Enliven Therapeutics, Inc.
ELVN
37 insider filings · Latest: Oct 14, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Oct 5 8:57 PM | Scott J. GarlandDirector | Sale | 13,000 | $46.67 | $606.7K | 0(D) | View → |
| Oct 1, 2026 | Oct 1 8:02 PM | JEFFREY GARLAND | Proposed Sale | 13,000 | $46.67 | $606.7K | — | View → |
| Sep 17, 2026 | Sep 21 9:23 PM | Benjamin HohlCHIEF FINANCIAL OFFICER | Sale | 6,018 | $50.35 | $303.0K | 38,000(D) | View → |
| Sep 17, 2026 | Sep 21 9:22 PM | Helen Louise CollinsCHIEF MEDICAL OFFICER | Sale | 5,000 | $50.35 | $251.8K | 25,000(D) | View → |
| Sep 17, 2026 | Sep 17 8:33 PM | Hohl Benjamin | Proposed Sale | 12,036 | $49.12 | $591.2K | — | View → |
| Sep 4, 2026 | Sep 4 6:58 PM | Heyman Richard A. | Proposed Sale | 38,000 | $59.29 | $2.3M | — | View → |
| Aug 17, 2026 | Aug 19 8:17 PM | Benjamin HohlCHIEF FINANCIAL OFFICER | Sale | 6,018 | $58.58 | $352.6K | 40,036(D) | View → |
| Aug 17, 2026 | Aug 19 8:16 PM | Helen Louise CollinsCHIEF MEDICAL OFFICER | Sale | 5,000 | $58.59 | $292.9K | 25,000(D) | View → |
| Aug 4, 2026 | Aug 7 12:18 AM | Mika K DerynckDirector | Sale | 158,795 | $60.21 | $9.6M | 0(D) | View → |
| Aug 4, 2026 | Aug 4 8:39 PM | Derynck Mika K | Proposed Sale | 158,795 | $58.04 | $9.2M | — | View → |
| Jul 17, 2026 | Jul 21 9:24 PM | Benjamin HohlCHIEF FINANCIAL OFFICER | Sale | 6,018 | $52.64 | $316.8K | 46,054(D) | View → |
| Jul 17, 2026 | Jul 21 9:23 PM | Helen Louise CollinsCHIEF MEDICAL OFFICER | Sale | 5,000 | $52.67 | $263.4K | 25,000(D) | View → |
| Jul 17, 2026 | Jul 17 8:36 PM | Collins Helen Louise | Proposed Sale | 15,000 | $50.86 | $762.9K | — | View → |
| Jul 6, 2026 | Jul 8 9:15 PM | Lori Anne KunkelDirector | Sale | 10,000 | $50.49 | $504.9K | 41,884(D) | View → |
| Jun 22, 2026 | Jun 24 11:19 PM | ORBIMED ADVISORS LLC10% Owner | Sale | 860,123 | $45.36 | $39.0M | 6,555,102(I) | View → |
| Jun 22, 2026 | Jun 23 12:13 AM | OrbiMed Genesis Master Fund, L.P. | Proposed Sale | 26,323 | $45.96 | $1.2M | — | View → |
| Jun 22, 2026 | Jun 23 12:10 AM | OrbiMed Private Investments VII, LP | Proposed Sale | 833,800 | $45.96 | $38.3M | — | View → |
| Jun 22, 2026 | Jun 23 12:08 AM | The Biotech Growth Trust PLC | Proposed Sale | 31,132 | $45.96 | $1.4M | — | View → |
| Jun 17, 2026 | Jun 22 9:13 PM | Benjamin HohlCHIEF FINANCIAL OFFICER | Sale | 6,018 | $43.80 | $263.6K | 51,000(D) | View → |
| Jun 17, 2026 | Jun 22 9:11 PM | Helen Louise CollinsCHIEF MEDICAL OFFICER | Sale | 5,000 | $43.80 | $219.0K | 25,000(D) | View → |
Page 1 of 7
Next →
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | Feb 18 12:57 AM | Scott J. GarlandDirector | Grant/Award | 1,427 | $27.16 | 1,427(D) | View → |
| Feb 12, 2026 | Feb 18 12:56 AM | Mika K DerynckDirector | Grant/Award | 17,126 | $27.16 | 17,126(D) | View → |
| Feb 12, 2026 | Feb 18 12:56 AM | Jake BauerDirector | Grant/Award | 17,126 | $27.16 | 17,126(D) | View → |
| Feb 12, 2026 | Feb 18 12:55 AM | Rahul D. BallalDirector | Grant/Award | 17,126 | $27.16 | 17,126(D) | View → |
| Feb 12, 2026 | Feb 18 12:53 AM | Anish PatelCHIEF OPERATING OFFICER | Grant/Award | 120,000 | $27.16 | 120,000(D) | View → |
| Feb 12, 2026 | Feb 18 12:52 AM | Joseph P LyssikatosCHIEF SCIENTIFIC OFFICER | Grant/Award | 112,500 | $27.16 | 112,500(D) | View → |
| Feb 12, 2026 | Feb 18 12:49 AM | Benjamin HohlCHIEF FINANCIAL OFFICER | Grant/Award | 150,000 | $27.16 | 150,000(D) | View → |
| Feb 12, 2026 | Feb 18 12:47 AM | Helen Louise CollinsCHIEF MEDICAL OFFICER | Grant/Award | 150,000 | $27.16 | 150,000(D) | View → |
← Previous
Page 2 of 2